Triple-Drug cocktail aims to boost remission in acute myeloid leukemia
NCT ID NCT05654194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether a combination of three drugs—azacitidine, venetoclax, and ATRA—can safely and effectively treat adults newly diagnosed with acute myeloid leukemia (AML). The drugs work together to stop cancer cell growth by demethylating DNA, promoting cell differentiation, and killing cancer cells. Participants receive the combination in cycles as induction, consolidation, and maintenance therapy. The main goal is to see how many patients achieve complete remission after the first cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- azacitidine, venetoclax, and ATRA (all-trans retinoic acid)
- What this could lead to
- If successful, this three-drug combination could offer a more effective initial treatment for acute myeloid leukemia, potentially leading to higher remission rates without the need for intensive chemotherapy.
- What could go wrong
- This is a single-arm, early-phase trial with a small number of participants, so results may not apply to all AML patients. The combination may cause significant side effects, and it is not yet known if it improves long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the First Affiliated Hospital of Soochow University
Suzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?